Diligence memo · auto-generated · as of July 2, 2026

Novilytic, LLC

Novilytic, LLC looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Novilytic, LLC operates in Biotechnology, based in WEST LAFAYETTE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Novilytic, LLC has raised $1.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $950K on 2021-03-31.

Most recent recorded round closed around 2025-12-01.

Valuation (modeled)modeled

Provath models Novilytic, LLC at approximately $1.0M (range $283K–$2.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.06× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (106% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 56 months.

Last raise 7 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 1.8× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 23% of Biotechnology peers (4293 compared).

Modeled value ranks above 3% of those peers.

Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.